A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

NCT03334084 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

argenx